Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma
Status:
Unknown status
Trial end date:
2018-07-01
Target enrollment:
Participant gender:
Summary
The study is aimed to evaluate the efficacy and safety of Apatinib and Irinotecan in patients
with recurrent high-grade glioma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First People's Hospital of Lianyungang
Collaborators:
Lianyungang Hospital Affiliated Bengbu Medical College Shandong Cancer Hospital and Institute Suzhou Kowloon Hospital The Affiliated Hospital of Medical College of Qingdao University Yankuang Group General Hospital